Not Yet RecruitingNot Applicable

Categorizing Patient Risk for Tricuspid Regurgitation (TR) Intervention With Admittance Pulmonary Artery Catheter System (APACS)

8 participantsStarted 2027-07-10

Plain-language summary

The study is focused on evaluation of the effectiveness of the Admittance Pulmonary Artery Catheter (PAC) system for assessing the right ventricular (RV) function in patients with tricuspid regurgitation (TR) prior to tricuspid valve intervention.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with severe or torrential TR who are already scheduled to undergo clinically indicated tricuspid valve (TV) percutaneous replacement or clipping to reduce heart failure symptoms Exclusion Criteria: * Children (defined as individual \<18 years of age) will be excluded from this study

What they're measuring

Obtain Ees/Ea consistent with non-invasive literature of TAPSE/PASP: CouplingRatio_ECHO-CouplingRatio_PAC ≤ 0.2 (unitless)

Timeframe: 1 year

Trial details

NCT IDNCT07500025

SponsorFeldman Cardiology, PLLC

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-07-10

View on ClinicalTrials.gov More Tricuspid Regurgitation (TR) trials